Esanex Announces Successful End-of-Phase 2 Meeting for SNX-5422 in Neuroendocrine Tumor
“While survival for all NETs has improved over time1 there remains an urgent need for new treatment options,” said Steve Hall, Ph.D., President and Chief Executive Officer of Esanex, Inc. “Based on positive results presented at the North American Neuroendocrine Society (NANETS) annual meeting in 2017, we believe that SNX-5422 has the potential to provide a new therapeutic approach for patients living with NETs. We are pleased with the outcome of our End-of-Phase 2 discussions with the FDA. We appreciate the valuable guidance the FDA has already provided us and look forward to continuing a constructive relationship as we advance our Phase 3 registration program.”
SNX-5422 was studied in combination with everolimus and showed promising signs of clinical activity in subjects with advanced NETs. The objective response rate in a subset of subjects who had entry criteria similar to that seen in the registrational study for everolimus alone (RADIANT-4) was 50%, compared to 2% seen in that study. Multiple subjects remained on the combination for prolonged periods of time, including 2 subjects for ≥30 months2.
SNX-5422 is a chemically unique, orally active Hsp90 inhibitor that has provided durable clinical responses in open label trials in non-small cell lung cancer (NSCLC) and neuroendocrine tumors (NET). With approximately 200 patients treated to date, SNX-5422 has a well-established safety profile that supports studying it as monotherapy and in combination with existing approved drugs in a variety of clinical settings.
Esanex is a clinical-stage company with new insights into Heat Shock Proteins as an important cancer target. Our lead program, SNX-5422, has shown durable clinical responses in rationally-designed combination studies in patients with neuroendocrine tumors and non-small cell lung cancer. www.esanexpharma.com
1 Dasari, A. et al Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States, JAMA Oncol. 2017 Oct 1;3(10):1335-1342.
2 Gutierrez et al. 2017; NANETS Philadelphia 2017, poster 249, Phase I, Open-label, Dose-escalation Study of SNX-5422 plus Everolimus in Neuroendocrine Tumors.